Our findings are hypothesis-generating and, if validated in larger studies that more directly integrate clinical data, could help guide the design of future biomarker studies that utilize FOLH1 as an integrated biomarker to guide angiogenic/VEGF-based treatment strategies for patients with RCC and potentially other solid tumor malignancies. This evidence concerns the gene VEGFA and renal cell carcinoma.